Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

TrojanDC - A BREAKTHROUGH DEEP-TECH INNOVATION FOR CANCER IMMUNOTHERAPY

Project description

Advancing first-in-class cancer immunotherapy

Current immunotherapies have limited effectiveness in treating cancer, creating a demand for innovative solutions. Asgard Therapeutics, a pre-clinical start-up, is developing cost-effective cancer immunotherapies through in vivo cell reprogramming. The EU-funded TrojanDC project aims to validate the company’s lead candidate, TrojanDC, an innovative immunotherapy that transforms cancer cells into antigen-presenting dendritic cells. This transformation enables the immune system to recognise and attack cancer cells, potentially overcoming the limitations of existing therapies. The Women TechEU grant will support the development of a roadmap for necessary IND studies and first-in-human clinical trials, as well as the creation of a business plan. The company is poised to advance this first-in-class cancer immunotherapy.

Objective

The Challenge: Cancer remains one of the major challenges to modern medicine affecting one-in-three people in Europe. Available immunotherapies are effective in a limited number of patients and often lose their efficacy due to heterogeneity and lack of tumor-antigen presentation. Despite these shortcomings, the global immune-oncology market is one of the fastest growing therapeutics markets. Large players like Merck, Pfizer, and Novartis have shown to be keen on acquisitions of high-potential technologies. There is thus an urgent need and high demand for innovative cost-effective immunotherapies consistently effective in a broader range of cancer patients.
The innovation: Asgard Therapeutics is a pre-clinical start-up company developing innovative cancer immunotherapies based in in-vivo cell reprogramming. The company is led by the scientific co-founder and CEO Cristiana Pires who, together with her co-founders, pioneered direct reprogramming to induce antigen-presenting dendritic cells. Asgard raised a € 6M seed round of funding to generate proof-of-concept for its lead candidate TrojanDC, a paradigm-shifting immunotherapy that reprograms cancer cells into antigen-presenting dendritic cells, allowing the presentation of their tumor antigens to the immune system, thereby eliciting potent anti-cancer immunity. TrojanDC has the potential to overcome challenges with current immunotherapies by reinstating cancer immunogenicity. The Women TechEU grant will allow defining a clear roadmap for the IND-enabling studies and FIH clinical trials and creating a comprehensive business plan required to raise Series A funding in Q4 2023.
The Impact: With strong proof-of-concept data already obtained, an exceptional team of high-performing scientists and a strong syndicate of seasoned VCs, Asgard Therapeutics is in a unique position to develop first-in-class cancer immunotherapy based in in-vivo reprogramming.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-CSA - HORIZON Coordination and Support Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIE-2022-SCALEUP-02

See all projects funded under this call

Coordinator

ASGARD THERAPEUTICS AB
Net EU contribution
€ 75 000,00
Address
MEDICON VILLAGE
223 81 Lund
Sweden
SME
Yes
Region
Södra Sverige Sydsverige Skåne län
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data